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Abstract
Background: It has been shown that a subgroup of patients with differentiated thyroid cancer (DTC) and
medullary thyroid carcinoma (MTC) would progress to advanced stages of thyroid cancer. Therefore, the present
study was done to systematically review available evidence in order to investigate efficacy and safety of peptide
receptor radionuclide therapy (PRRT) in the patients with advanced radioiodine refractory differentiated thyroid
cancer (RR-DTC) and metastatic MTC.
Methods: For this purpose, relevant studies investigated safety and efficacy of PRRT in the patients with advanced
RR-DTC and metastatic MTC were identified by searching Medline (Pubmed, Ovid, and Ebsco), Scopus, Embase,
Web of Science, and Cochrane Library databases (from database inception to March 24, 2021). The review was
performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA)
statement. Searching was done independently by two investigators. Two researchers independently extracted the
data and any disagreement was adjudicated by consensus. Quality of the studies was assessed using the tool of
case reports/series in systematic reviews.
Results: Among 2284 related papers, 41 papers met the inclusion criteria. A total of 157 patients with RR-DTC were
treated with PPRT. Biochemical and objective responses (partial and complete) were observed in 25.3 and 10.5% of
patients, respectively. Among 220 patients with metastatic MTC, biochemical and objective responses were
observed in 37.2 and 10.6% of the patients, respectively.
Forty-six deaths were reported in 95 patients with advanced RR-DTC. In addition, 63 deaths were observed in 144
patients with metastatic MTC. Major side effects were reported in 124 patients treated with 90Y -based agent. In the
patients treated with 177Lu-DOTA-TATE and 111In-Octreotide, mild and transient hematologic or renal
complications were reported.
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Conclusion: Findings of the study revealed that in the absence of the established treatment for the patients with
RR-DTC and metastatic MTC, PRRT could be effective with few adverse events.
Trial registration: PROSPERO registration number: CRD42019125245.
Keywords: Peptide receptor radionuclide therapy, Radioiodine refractory-differentiated thyroid Cancer, Medullary
thyroid carcinoma, Papillary thyroid carcinoma, Yttrium-90, 177Lu-DOTATATE, Indium-111, Systematic review
Background
Thyroid cancer is the most common endocrine malig-
nancy and its incidence has increased by 4.4% per year
during 2007–2011 [1, 2]. Differentiated thyroid cancer
(DTC), is the most frequent subtype of thyroid cancer
accounting for 85–95% of the cases [3, 4]. Medullary
thyroid cancer (MTC) originating from parafollicular or
C cells of the thyroid gland accounts for approximately
5% of all thyroid cancer cases [5].
The standard of treatment for most patients with DTC
includes thyroidectomy followed by radioiodine treat-
ment. A 10-year overall survival rate of 80–99% has been
reported among these patients [6]. However, in spite of
highly effective treatment strategies, there is a chance of
recurrence in 20% of the subjects. Radioactive iodine
plays a major role in diagnosis and treatment of recur-
rent disease [7]. However, some thyroid cancers are re-
sistant to radioiodine despite the elevated level of
thyroglobulin [8]. Radioiodine refractory-DTC (RR-
DTC) has shown aggressive clinical behavior and a 10-
year survival rate of 10% [9, 10]. Surgery and external
beam radiation therapy can be used to manage local dis-
ease but not in case of widespread metastases. Moreover,
chemotherapeutic agents have shown limited efficacy
with considerable side effects [11, 12].
MTC is inherently non-sensitive to radioactive iodine.
Hence, its management is more difficult and its progno-
sis is worse than DTC [7]. The overall survival rate is be-
tween 75 and 85% during 10 years for individuals with
MTC [13]. In spite of aggressive surgical treatment,
there is almost a 50% of chance for persistent or recur-
rent disease, with deleterious effects on quality of life
and the reduced 10-year survival rate by 40% [7, 13]. Re-
operation, embolization, and perhaps radiotherapy could
improve outcomes [14]. Meanwhile, response to conven-
tional chemotherapy is limited with life-threatening tox-
icity [7]. Currently, other therapeutic options are scarce
and not widely available.
There are few alternative treatments in the patients
with advanced RR-DTC. Somatostatin receptor (SSTR)
expression on cell surface of neuroendocrine and thyroid
tumors regulates cell proliferation [15]. Targeting SSTR
with radiotracer in peptide receptor radionuclide therapy
(PRRT) can induce tumor cell death. Overexpression of
somatostatin receptor subtypes on surface of cells is
required for PRRT and therefore, tumor remission can
be predicted based on the results of scintigraphy on
somatostatin receptor. Thus, PRRT could be a thera-
peutic option based on scintigraphy results of somato-
statin receptor. It has been used previously for treatment
of metastatic neuroendocrine tumor and advanced pheo-
chromocytomas and paragangliomas with high efficacy,
tolerability, and low toxicity [16, 17].
Accordingly, the present study was conducted to sys-
tematically review available evidence in order to investi-
gate efficacy and safety of PRRT in the patients with
advanced RR-DTC and metastatic MTC.
Methods
Search strategy and selection criteria
A systematic review was performed on the published
works to investigate safety and efficacy of PRRT in the
patients with advanced RR-DTC and metastatic MTC,
according to the preferred reporting items for systematic
reviews and meta-analyses (PRISMA) statement [18].
The study was registered before completing formal
screening of search results (PROSPERO registration
number: CRD42019125245).
Eligibility criteria
All the original studies containing data related to PRRT
were considered eligible to be included in the review
study. Exclusion criteria were irrelevant papers (based
on screening of titles and abstracts), papers with insuffi-
cient data available, duplications, and review papers. All
the eligible studies were included to assess efficacy, and/
or safety of PRRT.
Study identification
For this systematic review, the Cochrane Central Regis-
ter of Controlled Trials (Central), Medline (PubMed,
Ovid, and Ebsco), Scopus, and Embase databases were
searched (from database inception to March 24, 2021).
Search terms for English-language publications included:
“peptide receptor radionuclide therapy”, “PRRT”, “radio-
nuclide therapy”, “radiolabeled somatostatin analogues”,
“thyroid cancer”, “thyroid carcinoma”, “thyroid neo-
plasm”, “differentiated thyroid cancer”, “differentiated
thyroid carcinoma”, “differentiated thyroid neoplasm”,
“medullary thyroid cancer”, “medullary thyroid
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carcinoma”, and “medullary thyroid neoplasm”. Details
regarding the search strategy are provided in the Supple-
mentary Table 1.
The first search was done independently by two in-
vestigators (ZE and ZM). Also, a complete updated
search was performed on all databases available and
new studies (if any exist) were identified to assess the
details and incorporate findings in this review. The
snowballing techniques were used to complete the
search by screening reference lists of the included pa-
pers for relevant studies. Also, registry of prospective
studies with accessible results was searched. Two au-
thors (RM, ZM) independently determined studies
that should be evaluated further by scanning the title,
abstract, or both based on the inclusion/exclusion cri-
teria, the reviewers were blinded to names of the
journals and authors. All the potentially relevant pa-
pers as full texts were assessed and any disagreements
were resolved by consensus or by arbitration of two
experts (MK and MM). In case of duplicates or mul-
tiple publications of a primary study, yield of informa-
tion was enhanced by collating all available data and
using the most complete data set aggregated across
all the known publications.
Data collection and management
Two reviewers (RM and ZM) independently extracted
the data from the included trials and any disagree-
ment was adjudicated by consensus or by arbitration
of other reviewers (MK and MM). Published reports
were obtained for every study, and standard informa-
tion was extracted in a spreadsheet. The following
data were extracted: author’s name; year of publica-
tion; country where the study was performed; number
of participants, sex and age of the participants; tumor
classification, site of metastases; prior treatments (cu-
mulative radioiodine in RR-DTC); cumulative activity
(GBq) of PRRT; response to treatment criteria; time
to progression (TTP); follow-up duration; response to
treatment; complications (major/minor); mortality
rate; and time to death.
Biochemical response was defined in the patients
with DTC based on serum thyroglobulin (Tg) level
and in the patients with MTC, it was defined based
on serum calcitonin and carcino- embryonic antigen
(CEA) levels. Different criteria were used to evaluate
radiological responses to treatment, namely world
health organization (WHO) criteria, response evalu-
ation criteria in solid tumors (RECIST) criteria, and
southwest oncology group (SWOG) criteria [19].
Moreover, the European organization for research and
treatment of cancer (EORTC) has classified metabolic
response to treatment based on the maximum stan-
dardized uptake value (SUVmax) [20].
For further analysis, proportions of complete and par-
tial radiologic response were integrated as “objective
response”.
Occurrence of adverse events was evaluated using
common terminology criteria for adverse events (CTCA
E) [21]. Two reviewers (RM and ZM) independently
assessed methodological quality of the included studies
using the tool of systematic reviews [22], and any dis-
agreement was resolved by consensus.
Results
Search on the literature led to identification of 2284
publications, of which 98 papers were reviewed in full
text (Fig. 1. shows flow chart of literature search and
paper selection). The risk of bias of the included studies
was low (Supplementary Table 2). Inter-reviewer’s agree-
ment was “excellent” for the selected papers (Cohen’s
test κ = 0.96). Among 41 publications met the inclusion
criteria, 12 papers were retrospective in terms of design;
19 papers were prospective studies and remaining 10 pa-
pers were case reports. Tables 1 and 2 summarize char-
acteristics of the included studies assessing efficacy of
PRRT in the patients with advanced RR-DTC, and meta-
static MTC, respectively. Data regarding safety of PRRT
are presented in Table 3. Cumulative activity of PRRT
ranged between 0.925–83.2 GBq. For 90Y -based agent,
most of the studies had used this agent with an adminis-
tered activity ranging from 0.925 to 5.9 GBq per cycle
usually up to 4 cycles. For 177Lu-DOTA-TATE, the ad-
ministered activity rate was between 5.5–7.7 GBq per
cycle usually up to 4 cycles. In terms of follow-up dur-
ation, in the patients with advanced RR-DTC, it was be-
tween 1 and 99months after commencement of PRRT
(median: 12 months). It was between 1 and 144months
(median: 17 months) in the patients with metastatic
MTC. Death was recorded in 109 patients. Time to
death varied from 1 to 63months (median: 11 months).
It should be noted that more than one criterion was
used to evaluate efficacy of PRRT, and some patients did
not complete their full course of treatment.
Efficacy of PRRT in RR-DTC
Overall, 157 patients with advanced RR-DTC were
treated with PRRT. Based on biochemical response cri-
teria, from 79 treated patients, 20 cases of partial re-
sponse (PR), 22 cases of stable disease (SD), and 37
cases of persistent disease (PD) were determined. Out of
91 patients whose radiological response was assessed, 9
cases of PR, 39 cases of SD, and 43 cases of PD were re-
corded. Metabolic response was evaluated in 48 patients.
Six cases of PR, 20 cases of SD, and 22 cases of PD were
identified.
In 85 patients treated with 90Y -based agent; 44 pa-
tients were assessed based on biochemical response
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among whom 8 cases of PR, 14 cases of SD, and 22 cases
of PD were observed. Seven cases of PR, 23 cases of SD,
and 25 cases of PD were identified in 55 patients
assessed based on radiological response. Moreover, 2
cases of PR, 5 cases of SD, and 4 cases of PD were re-
ported in 11 patients assessed based on metabolic
response.
In 26 patients treated with Lutetium-177 -based agent,
10 cases of PR, and 11 cases of PD showed biochemical
response. Considering 20 patients assessed for radio-
logical response, 2 cases of PR, 9 cases of SD, and 9
cases of PD were reported. Out of 9 patients assessed for
metabolic response, 1 case of PR, 4 cases of SD, and 4
cases of PD were identified.
Moreover, in 18 patients treated with Indium-111, bio-
chemical response was assessed in 14 patients. Two pa-
tients with PR, 8 cases with SD, and 4 cases with PD
were reported. Seven SD cases and 9 PD cases were re-
corded based on radiological response in 16 patients.
Among 157 patients with RR-DTC, biochemical and
objective responses (partial and complete) were observed
in 25.3 and 10.5% of the patients, respectively.
Efficacy of PRRT in metastatic MTC
In total, 220 patients with metastatic MTC were treated
with PRRT. Based on biochemical response to the treat-
ment in 145 patients, 7 cases of complete response (CR),
47 cases of PR, 20 cases of SD, and 71 cases of PD were
recognized.
Radiologic response was evaluated among 134 patients.
Four cases of CR, 9 cases of PR, 75 cases of SD, and 46
cases of PD were observed. Considering metabolic re-
sponse among 46 patients, 7 cases of PR, 29 cases of SD,
and 10 cases of PD were identified.
Sixty-nine patients were treated by 90Y-DOTATOC,
88 patients were treated with 177Lu-DOTA-TATE, and
12 patients were treated with 111_Indium -based agent.
Type of treatment was unknown in other patients.
In 69 patients treated with 90Y-DOTATOC, 1 case of
CR, 15 cases of PR, 4 cases of SD, and 35 cases of PD
(based on biochemical response criteria in 55 patients)
as well as 2 cases of CR, 21 cases of SD and 15 cases of
PD (based on radiological response criteria in 38 pa-
tients) and 1 case of PR and 1 case of PD (based on
metabolic response criteria in 2 patients) were reported.
Out of 74 patients treated with 177Lu-DOTA-TATE, 5
cases of CR, 26 cases of PR, 14 cases of SD, and 29 cases
of PD were observed based on biochemical response cri-
teria. Moreover, 9 cases of PR, 50 cases of SD, and 26
cases of PD were achieved in 85 patients based on radio-
logical response criteria. Furthermore, SD was found in
3 patients based on metabolic response criteria. In the
patients treated with 111_Indium -based agent; 1 case of
CR, 2 cases of SD, and 4 cases of PD (in 7 patients
Fig. 1 Flow chart of literature search and article selection
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assessed based on biochemical response) and also, 2
cases of CR, 4 cases of SD, and 5 cases of PD (in 11 pa-
tients assessed based on radiological criteria) were
reported.
Overall, in the patients with metastatic MTC, bio-
chemical and objective responses were observed in 37.2
and 10.6% of the patients, respectively.
Safety of PRRT
Safety of PRRT was assessed in 19 studies (totally, 239
patients). Death was observed in 109 patients. In
addition, time to death varied from 1 to 63 months.
In 95 patients with advanced RR-DTC, 46 patients
died. Time to death ranged from 1 to 63months from
commencement of PRRT. Based on type of PRRT, death
occurred in 29/55 patients treated with 90Y -based agent,
6/17 patients treated with 177Lu-DOTA-TATE, and 8/
16 patients treated with 111In-Octreotide. Among 44
patients with metastatic MTC, 63 patients died. Time to
death ranged from 1 to 26.8 months since initiating the
first course of PRRT. Based on the type of PRRT, death
occurred in 27/69 patients treated with 90Y-DOTATOC,
31/63 patients treated with 177Lu-DOTA-TATE, and 4/
5 patients treated with 111In- Octreotide. Major side ef-
fects were reported in 124 patients treated with 90Y
-based agent. Fourteen patients developed renal toxicity
(2 cases of grade 4, 2 cases of grade 3, 2 cases of grade 2,
and 8 cases of grade 1). Furthermore, hematologic tox-
icity was observed in 64 patients (3 cases developed
grade 4 of thrombocytopenia, and 1 patient reported to
suffer from grade 4 of anemia). Moreover, in 80 patients
treated with 177Lu-DOTA-TATE, mild and transient
hematologic and renal complications were reported (4
patients with grade 1 and one case with grade 2 of
hematologic toxicity and one patient with grade 2 of
renal toxicity). Among 21 patients treated with 111In-
Octreotide, one patient developed transient
thrombocytopenia (grade1).
Discussion
Herein, a comprehensive systematic review was done to
investigate efficacy and safety of PRRT in management
of advanced RR-DTC and metastatic MTC. The results
suggested that PRRT could maintain disease stability
with few adverse events. In short-term, toxicity is mild
and transient. In addition, long-term toxicity is rare and
with low grade. To the best of our knowledge, no similar
systematic review or meta-analysis has been done previ-
ously to investigate efficacy and safety of PRRT in RR-
DTC and metastatic MTC.
There are few recommended treatments for the pa-
tients with RR-DTC and therapeutic options are associ-
ated with certain limitations in case of the patients with
metastatic DTC. The choice of treatment depends on
bulk of the tumor. Simple observation, multi-targeted, or
mutation-selected kinase inhibitors (MKI), and trad-
itional cytotoxic chemotherapy are the available options
[12, 62]. Despite approval of doxorubicin by the food
and drug administration (FDA), treatment with cytotoxic
agents has shown disappointing results [63]. Therefore,
benefit-risk ratio must be carefully evaluated before
starting treatment [62].
For majority of the patients with MTC, primary sur-
gery is curative at early stages. However, local and dis-
tant metastases after surgery are the major causes of
mortality [14]. Resurgery, chemotherapy, external beam
radiation therapy, and biological agents, such as RET
and MEK inhibitors have yielded disappointing and lim-
ited results. Although, treatment with tyrosine kinase in-
hibitors (TKIs) (Vandetanib and Cabozantinib) improves
progression-free survival (PFS), severe adverse events
could limit the use of them. There is no curative





















































Abbreviations: Na Not Available, RR-DTC Radioiodine-Refractory Differentiated Thyroid Cancer, FTC Follicular Thyroid Carcinoma, PTC Papillary Thyroid Carcinoma,
HCTC Hurtle Cell Thyroid Carcinoma, MTC Medullary Thyroid Carcinoma
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treatment for these patients, and all the available treat-
ment modalities have been shown to have certain limita-
tions and complications [6].
In the 1990s, the role of SSTR in regulation and
proliferation of normal thyroid cells and tumoral tis-
sues was reported that led to introduction of peptide
receptor imaging and PRRT in management of meta-
static MTC and advanced RR-DTC [15]. Type of
SSTRs expression could have an effect on survival
rate of these patients [64]. From 5 subtypes of SSTR
described in human cells, SSRT2 is expressed in
MTC [7]. However, SSRT2 expression has not been
identified in papillary or follicular thyroid cancer, and
it is irregularly expressed in Hurthle cell adenoma
and Hurthle cell carcinoma [65].
Generally, PRRT is able to deliver a high dose of radi-
ation to intracellular components of cancer cells, and in-
duce tumor shrinkage [7]. Currently, PRRT is
considered as a safe and effective treatment modality for
metastatic inoperable well-differentiated neuroendocrine
tumors and advanced pheochromocytomas and paragan-
gliomas [16, 17].
The most frequently used radionuclides in PRRT are
90Y and Lutetium-177. They have different physical
characteristics, namely different emission ranges. This
results in various maximum tissue penetrations ranging
from 3mm for Lutetium-177 to 12mm for 90Y. Since,
90Y has the highest energy and maximum tissue penetra-
tion; it is a preferable radionuclide for tumors with large
size and poor vascularization. On the other hand,
Lutetium-177 emits intermediate-energy suitable for
small-sized tumors. Few studies had used 111In-
Octreotide, with tissue penetration ranging from 0.2 to
10mm (Table 1) [7]. Krenning et al., for the first time
reported treatment of the patients with advanced DTC
with 111In-Octreotide analogs. One patient, who re-
ceived total cumulative activity of at least 20 GBq
showed disease stabilization [40]. In a pilot study con-
ducted in Netherlands, 9 patients with advanced RR-
DTC were treated with high, fixed doses of 111In
-Octreotide. Six months after the last therapy, 4 patients
had SD, and 5 patients showed PD. Mean Tg value was
higher in PD cases than patients with SD. They con-
cluded low Tg value could have a positive effect on the
outcome [41].
Görges et al., in a study regarding the first cases of
treatment with 90Y-DOTATOC in 3 patients with ad-
vanced RR-DTC and pulmonary metastasis showed de-
celeration in short-term disease progression [26]. In the
last report on treatment with 90Y-DOTATOC in RR-
DTC, median survival was found to be 21months from
initiating the first course of PRRT with only minor and
transient hematological toxicity in some patients [15].
Recently, 177Lu-DOTA-TATE has been used more than
90Y but, number of patients treated with this somato-
statin analog was limited.
In the patients with metastatic MTC, limited experi-
ence with PRRT treatment has been reported. Results of
a study on the patients with metastatic MTC suggested
that treatment with 90Y-DOTATOC is associated with a
long-term survival benefit. However, treatment response
was independent of pre-treatment scintigraphy results
[45]. Recently, Beukhof et al., reported 17 years of expe-
riences with 177Lu-octreotate treatment. They con-
cluded that this treatment could be considered as a
treatment in the patients with high uptake on 111In-
DTPA-Octreotide scan (uptake grade 3) and positive
SSTR2a expression in tumor histology [54]. Budiawan
et al., found that the patients with RR-DTC having good
response had less undergone other treatment modalities
prior to PRRT than non-responders. In addition, they in-
troduced lung metastasis as a poor prognostic factor for
survival after PRRT [6].
However, PRRT is not free from adverse effects and
minor complications,such as nausea, asthenia, and eleva-
tion in liver enzyme level are observed in up to 16.7% of
patients, while major complications,such as nephrotox-
icity and hematologic adverse events are rare and transi-
ent [23, 24]. Proximal tubular reabsorption of radio
peptide and its interstitial retention lead to glomerular
fibrosis [40], which is markedly observed after treatment
with 90Y-DOTATOC. Hence, kidney protection is
mandatory along with co-administration of positively-
charged amino acids,such as L-lysine and/or L-arginine
competitively inhibiting proximal tubular reabsorption
of the radio peptide, or prolonged infusion over 10 h to
2 days after administration of radio peptide. Despite kid-
ney protection, loss of renal function may become clinic-
ally evident years after PRRT, especially after
administration of 90Y- DOTATOC. Sporadic reported
cases of delayed renal failure have received activities
greater than 7.4 GBq /m2 in very few cycles, without
kidney protection [61]. Cumulative and per-cycle renal
uptake dose, age, hypertension, diabetes and previous
chemotherapy with nephrotoxic agents could accelerate
the decrease in renal function after PRRT [66]. Consid-
ering these risk factors, one can modify treatment plan
or change choice of radio peptide based on burden of tu-
mors. Hematologic side effects generally are mild and
temporary,such as reduction in count of lymphocytes
and platelets [57].
Our systematic review demonstrated that treatment
with PRRT not only could lead to minor complications
in approximately 10% of cases but also it can cause very
rare and transient major complications.
This systematic review benefited from a comprehen-
sive search conducted by two independent investigators,
no time limits, independent reviews by two reviewers,
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and no publication bias. However, the main limitation of
the present study was low quality of the available evi-
dence. However, other underlying problems and limita-
tions included retrospective nature of the studies, a
selection bias, the amount of radioactivity administered
(1–83 GBq), non-uniform response criteria, huge differ-
ence in follow-up periods (1–99months),and the limited
number of patients per report. Also, our search was re-
stricted to English -language papers.
This systematic review investigated efficacy and safety
of PRRT in treatment of RR-DTC and metastatic MTC.
Given paucity of evidence, it is recommended to perform
further multi-center randomized controlled clinical
trials.
Conclusions
According to findings of our study, due to lack of vari-
ous treatment modalities, PRRT could be an option for
treatment of advanced RR-DTC, as well as metastatic
MTC, with few adverse events.
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